HIV/AIDS epidemic in India

HIV/AIDS epidemic in India
Name	HIV/AIDS epidemic in India
Disease	Human immunodeficiency virus infection and acquired immune deficiency syndrome

HIV/AIDS epidemic in India is the course and consequences of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) within the Republic of India. The epidemic has involved interactions among public health institutions, affected communities, nongovernmental organizations, research institutes, and international partners, shaping clinical practice, prevention strategies, and policy responses. Indian states and territories have displayed heterogeneous incidence and prevalence patterns driven by concentrated epidemics among key populations.

Background and Epidemiology

India's modern surveillance of HIV began after identification of cases linked to blood transfusion and injecting drug use in the late 1980s, with early reports from National AIDS Control Organisation partners and regional laboratories such as All India Institute of Medical Sciences sentinel sites. Epidemiological estimates have been produced by collaborations including National Institute of Epidemiology, World Health Organization, UNAIDS, and academic centers like Tata Memorial Centre and Christian Medical College, Vellore. Prevalence has varied by state—higher in states such as Manipur, Nagaland, Andhra Pradesh, and Tamil Nadu and lower in states such as Goa and Gujarat—with concentrated epidemics among groups served by clinics in urban hubs like Mumbai, Kolkata, Chennai, and New Delhi. Surveys by the National Family Health Survey and programmatic data from National AIDS Control Organisation have informed modeling by Institute of Medicine and global assessments by UNAIDS.

Transmission and Risk Factors

Transmission drivers in India have included heterosexual transmission in clusters connected to migrant labor routes such as those from Punjab and Uttar Pradesh to metropolitan centers, and parenteral exposure among people who inject drugs in northeastern corridors near Myanmar and Bangladesh. Key populations with elevated risk have included sex workers linked to red-light districts in Sonagachi and trucker networks along national highways managed by transport hubs like Delhi's Inter-State Bus Terminus, men who have sex with men frequenting urban venues monitored by community groups, and people who inject drugs associated with border towns in Manipur. Health-system related risks have historically involved unsafe injection practices and blood transfusion safety issues addressed by institutions such as Indian Council of Medical Research and blood banking reforms inspired by lessons from outbreaks in hospital settings like regional medical colleges. Co-factors such as co-infection with Mycobacterium tuberculosis and sexually transmitted infections identified at tertiary centers have amplified transmission and clinical progression.

Prevention and Public Health Interventions

Prevention strategies in India have combined targeted interventions, behavior-change communication, harm reduction, and biomedical approaches. Programmatic initiatives were implemented by National AIDS Control Organisation in phases, working with international partners such as World Bank, UNAIDS, and bilateral donors. Community-led interventions by NGOs including Durbar Mahila Samanwaya Committee in Kolkata and APAS-affiliated groups collaborated with clinics at institutions like St. John's Medical College and public health programs in states such as Kerala. Harm reduction services, needle exchange, and opioid substitution therapy were scaled up in northeast states in partnership with National Institute of Social Defence recommendations. Condom promotion relied on social marketing through outlets associated with commercial chains and civil society networks in urban areas like Bangalore and Hyderabad. Biomedical prevention progressed with voluntary counseling and testing sites, prevention of parent-to-child transmission programs at maternity wards in hospitals such as KEM Hospital, Pune, and later pre-exposure prophylaxis trials run by research institutes.

Treatment, Care, and Antiretroviral Therapy

Antiretroviral therapy (ART) rollout in India was guided by policy from Ministry of Health and Family Welfare and implementation by National AIDS Control Organisation via regional ART centers at tertiary hospitals including AIIMS and PGIMER, Chandigarh. Domestic pharmaceutical capacity centered on companies in regions like Gujarat enabled generic production of antiretrovirals following intellectual property debates involving actors such as World Trade Organization-related processes and civil society advocates. Clinical management integrated opportunistic infection protocols from Indian Council of Medical Research and co-management of tuberculosis with programs like Revised National Tuberculosis Control Program. Community-based organizations, including networks of people living with HIV such as NNP+-affiliated groups, provided adherence support, palliative care linkages, and psychosocial services.

Social Impact, Stigma, and Human Rights

The epidemic intersected with issues of stigma, discrimination, and human rights litigated in forums like the Supreme Court of India and addressed by legal advocacy organizations. Stigma affected employment in informal sectors in cities such as Mumbai and access to healthcare in rural districts across states like Bihar and Rajasthan. Civil society coalitions, including human rights NGOs and networks of migrants from regions like Northeast India, campaigned for anti-discrimination policies, confidentiality protections, and access to social security schemes administered by ministries and state departments. Media coverage by national outlets and documentaries produced by filmmakers and broadcasters contributed to public discourse and policy pressure.

Government Policy, Programs, and Funding

National policy responses were organized in multi-phase strategies by National AIDS Control Organisation with funding and technical cooperation from World Bank, bilateral partners, and domestic allocations from the Ministry of Health and Family Welfare. State AIDS Control Societies in jurisdictions such as Maharashtra and Karnataka implemented localized programs, while procurement systems engaged public sector undertakings and private manufacturers in industrial clusters around Ahmedabad. Policy debates over intellectual property, pricing, and access involved institutions like Department of Pharmaceuticals, international trade forums including WTO, and public interest litigants in the Supreme Court of India.

Research, Surveillance, and Future Challenges

Ongoing research and surveillance are led by institutions including National Institute of Virology, National AIDS Research Institute, and university departments at University of Hyderabad and Jawaharlal Nehru University. Challenges ahead include sustaining financing amid competing health priorities, addressing concentrated epidemics among key populations in urban centers and border regions, integrating HIV services with noncommunicable disease programs, and leveraging advances from global research networks such as International AIDS Society and trial consortia. Strengthening laboratory networks, improving data systems coordinated with National Health Mission, and protecting human rights remain central to future epidemic control efforts.

Category:Health in India Category:HIV/AIDS by country